United States

People: Inovio Pharmaceuticals Inc (INO.O)

INO.O on Nasdaq

16 Aug 2019
Change (% chg)

$0.18 (+8.22%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Kim, Jong 

Dr. Jong Joseph Kim is the President, Chief Executive Officer, Director of Inovio Pharmaceuticals Inc. Dr. Kim qualifies to serve on our Board given his broad experience as described below and his experience as our Chief Executive Officer. He was co-founder of VGX Pharmaceuticals, Inc., or VGX, and also served as its former President, Chief Executive Officer and a director from 2000 to June 2009. He previously worked at Merck & Company, Inc. developing vaccines. An immunologist by training, Dr. Kim holds an undergraduate degree from the Massachusetts Institute of Technology (MIT), a Ph.D. in biochemical engineering from the University of Pennsylvania, and an MBA from The Wharton School at the University of Pennsylvania. He has published more than 100 scientific papers, holds numerous patents, and sits on editorial boards and scientific review panels. In 2015, Dr. Kim was named Entrepreneur of the Year for Life Sciences by Ernst and Young in the Philadelphia region. He also serves on the board of the International Vaccine Institute and the Council of Korean Americans. The World Economic Forum selected Dr. Kim as a member of its Global Agenda Council and named him a Technology Pioneer as well as one of its Young Global Leaders. He is a frequent guest on CNBC’s Fast Money and other financial programs, where he comments on our breakthroughs and the pharmaceutical landscape. MIT’s Technology Review magazine called him "one of the world’s top innovators." Dr. Kim is a Fellow of the inaugural class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network where he is working with a team to develop a vision of tomorrow’s healthcare system.

Basic Compensation

Total Annual Compensation, USD 1,134,180
Restricted Stock Awards, USD 1,545,690
Long-Term Incentive Plans, USD --
All Other, USD 401,172
Fiscal Year Total, USD 3,081,040

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Simon Benito


Jong Kim


Peter Kies


Jacqueline Shea


Laurent Humeau


David Weiner

As Of  30 Dec 2018